Julie A. Kish, MD, FACP

BOARD CERTIFICATION:
          •  Medical Oncology

FELLOWSHIP:
          •  Wayne State University School of Medicine

RESIDENCY:
          •  Wayne State University School of Medicine

MEDICAL SCHOOL:
          •  Wayne State University - MD

• May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck. 2013 Mar. Pubmedid: 23468387.


• Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec;84(5):1198-1205. Pubmedid: 22749632. Pmcid: PMC3465463.


• Cooper J, Pajak T, Forastiere A, Jacobs J, Saxman S, Kish J, Kim H, Cmelak A, Rotman M, Machtay M, Ensley J, Chao K, Schultz J, Lee N, Fu K. Postoperative concurrent chemotherapy and radiation therapy in high-risk squamous cell carcinoma of the head & neck region: the RTOG 9501/intergroup phase III trial. New England J Med. 2004;350(19):1937-1944. Pubmedid: 15128893.


• Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan;21(1):92-98. Pubmedid: 12506176.


• Kish J, Bukkapatnam R, Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control. 2001;8(6):487-495. Pubmedid: 11807418.


• Kish J. Neoadjuvant androgen ablation in localized carcinoma of the prostate. Cancer Control. 2001;8(2):155-162. Pubmedid: 11326170.


• Kish J, Benedetti J, Balcerzak S, Veith R, Davis R, Pollock T, SchullerDE, Ensley J. Feasibility trial of postoperative radiotherapy and cisplatin followed by three courses of 5-FU and cisplatin in patients with resected head and neck cancer: a Southwest Oncology Group study. Cancer J Sci Am. 1999 Sep;5(5):307-311. Pubmedid: 10526672.


• Kish J, Wolf M, Schellhammer P, Hussain M, Einstein A, Crawford E. Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial. Am J Clin Oncol. 1997 Aug;20(4):327-330. Pubmedid: 9256883 .


• Elias L, Blumenstein B, Kish J, Flanigan R, Wade J, Lowe B, Goodwin J, Crawford E. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. Cancer. 1996 Sep;78(5):1085-1088. Pubmedid: 8780547 .


• DiBenedetto J J, Cubeddu L, Ryan T, Kish J, Sciortino D, Beall C, Eisenberg P, Henderson C, Griffin D, Wentz A. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther. 1995 Nov;17(6):1091-1098. Pubmedid: 8750400 .


• Kish J, Wolf M, Crawford E, Leimert J, Bueschen A, Neefe J, Flanigan R. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinom:a Southwest Oncology Group Study. Cancer. 1994 Aug;74(3):916-919. Pubmedid: 8039119 .


• Beck T, Hesketh P, Madajewicz S, Navari R, Pendergrass K, Lester E, Kish JA, Murphy W, Hainsworth J, Gandara D, et a. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992 Dec;10(12):1969-1975. Pubmedid: 1453211 .


• Cheruku R, Tapazoglou E, Ensley J, Kish J, Cummings G, al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer. 1991 Dec;68(12):2621-2624. Pubmedid: 1933812 .


• Higano C, Goodman P, Craig J, Kish J, Rivkin S, Wolf M, Crawford E. Phase II evaluation of amonafide in renal cell carcinoma: a Southwest Oncology Group study. Invest New Drugs. 1991 Nov;9(4):361-363. Pubmedid: 1804814 .


• al-Sarraf M, Kish J, Ensley J. The Wayne State University experience with adjuvant chemotherapy of head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug;5(4):687-700. Pubmedid: 1890060 .


• Kish J, Kopecky K, Samson M, Von Hoff D, Fletcher W, Kempf R, Muggia F. Evaluation of fludarabine phosphate in malignant melanoma: a Southwest Oncology Group study. Invest New Drugs. 1991 Feb;9(1):105-108. Pubmedid: 1709151 .


• Kish J. Rehabilitation of head and neck cancer patients: Consensus on recommendations from the international conference on rehabilitation of the head and cancer patient. Head Neck. 1991 Jan;13(1):1-14. Review. Pubmedid: 1989924 .


• Kuebler JP, Goodman PJ, Brown TD, Crawford ED, Reitz CL, Knight WA, Kish JA. Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study. Invest New Drugs. 1990 Aug;8(3):307-309. Pubmedid: 2125585.


• Kish J, Ensley J, al-Sarraf M. Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma. Am J Clin Oncol. 1990 Feb;13(1):17-18. Pubmedid: 2305717 .


• Kish JA, Ensley JF, al-Sarraf M. Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma. Am J Clin Oncol. 1990 Feb;13(1):17-18. Pubmedid: 2305717.


• de Braud F, Heilbrun L, Ahmed K, Sakr W, Ensley J, Kish J, Tapazoglou E, al-Sarraf M. Metastatic squamous cell carcinoma of an unknown primary localized to the neck: advantages of an aggressive treatment. Cancer. 1989 Jul;64(2):510-515. Pubmedid: 2736495 .


• Ensley J, Maciorowski Z, Hassan M, Pietraszkiewicz H, Heilbrun L, Kish J, Tapazoglou E, Jacobs J, al-Sarraf M. Cellular DNA content parameters in untreated and recurrent squamous cell cancers of the head and neck. Cytometry. 1989 May;10(3):334-338. Pubmedid: 2714116 .


• Ensley J, Patel B, Kloner R, Kish J, Wynne J, al-Sarraf M. The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs. 1989 Apr;7(1):101-109. Pubmedid: 2737845 .


• Ensley J, Kish J, Weaver A, Jacobs J, Hassan M, Cummings G, Al-Sarraf M. The correlation of specific variables of tumor differentiation with response rate and survival in patients with advanced head and neck cancer treated with induction chemotherapy. Cancer. 1989 Apr;63(8):1487-1492. Pubmedid: 2924257 .


• Kish J, Ensley J, Jacobs J, Binns P, al-Sarraf M. Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol. 1988 Oct;11(5):553-557. Pubmedid: 3177258 .


• Tapazoglou E, Kish J, Ensley J, Al-Sarraf M. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report. Am J Clin Oncol. 1988 Aug;11(4):474-478. Pubmedid: 3407628 .


• Al-Kourainy K, Crissman J, Ensley J, Kish J, Kelly J, Al-Sarraf M. Excellent response to cis-platinum-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma. Am J Clin Oncol. 1988 Aug;11(4):427-430. Pubmedid: 2457306 .


• LoRusso P, Tapazoglou E, Kish J, Ensley J, Cummings G, Kelly J, al-SarrafM. Chemotherapy for paranasal sinus carcinoma: a 10-year experience at Wayne State University. Cancer. 1988 Jul;62(1):1-5. Pubmedid: 2454717 .


• Ensley J, Kish J, Tapazoglou E, Jacobs J, Weaver A, Atkinson D, Ahmed K, Mathog R, Al-Sarraf M. An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancer. J Clin Oncol. 1988 Jul;6(7):1147-1153. Pubmedid: 3292714 .


• Jacobs J, Weaver A, Ahmed K, Crissman J, Ensley J, Kish J, Cummings G, al-Sarraf M. Proto-chemotherapy in advanced head and neck cancer. Head Neck Surg. 1987 Nov;10(2):93-98. Pubmedid: 3333768 .


• Patel B, Kloner R, Ensley J, Al-Sarraf M, Kish J, Wynne J. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci. 1987 Oct;294(4):238-243. Pubmedid: 3661619 .


• Ensley J, Maciorowski Z, Pietraszkiewicz H, Hassan M, Kish J, Al-Sarraf M, Jacobs J, Weaver A, Atkinson D, Crissman J. Solid tumor preparation for clinical application of flow cytometry. Cytometry. 1987 Sep;8(5):488-493. Pubmedid: 3665673 .


• Ensley J, Maciorowski Z, Pietraszkiewicz H, Klemic G, KuKuruga M, SaparetoS, Corbett T, Crissman J, Kish J. Solid tumor preparation for flow cytometry using a standard murine model. Cytometry. 1987 Sep;8(5):479-487. Pubmedid: 2444398 .


• Al-Sarraf M, Metch B, Kish J, Ensley J, Rinehart J, Schuller D, Coltman CAJr. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep. 1987 Jul;71(7-8):723-726. Pubmedid: 3300967 .


• Al-Kourainy K, Kish J, Ensley J, Tapazoglou E, Jacobs J, Weaver A, CrissmanJ, Cummings G, Al-Sarraf M. Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer. 1987 Jan;59(2):233-238. Pubmedid: 2433016 .


• Jacobs J, Kish J, Ensley J, Ahmad K, Weaver A, Crissman J, Al-Sarraf M. Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer. Am J Surg. 1986 Oct;152(4):451-455. Pubmedid: 2429570 .


• Kish J, Ensley J, Al-Sarraf M. Phase II evaluation of diaziquone in recurrent head and neck cancer. Cancer Treat Rep. 1986 May;70(5):671-672. Pubmedid: 3708616 .


• Tapazoglou E, Kish J, Ensley J, Al-Sarraf M. The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer. 1986 Mar;57(6):1105-1109. Pubmedid: 3943034 .


• Ensley J, Crissman J, Kish J, Jacobs J, Weaver A, Kinzie J, Cummings G, Al-Sarraf M. The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy. Cancer. 1986 Feb;57(4):711-717. Pubmedid: 3943009 .


• Kish J, Ensley J, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985 Dec;56(12):2740-2744. Pubmedid: 3902199 .


• Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer. 1985 Mar;55(5):1123-1128. Pubmedid: 4038469 .


• Kish J, Al-Sarraf M. Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck. Am J Clin Oncol. 1984 Oct;7(5):535-537. Pubmedid: 6507374 .


• Weaver A, Fleming S, Ensley J, Kish J, Jacobs J, Kinzie J, Crissman J, Al-Sarraf M. Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer. Am J Surg. 1984 Oct;148(4):525-529. Pubmedid: 6207742 .


• Ensley J, Jacobs J, Weaver A, Kinzie J, Crissman J, Kish J, Cummings G, Al-Sarraf M. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 1984 Sep;54(5):811-814. Pubmedid: 6204738 .


• Weaver A, Flemming S, Kish J, Vandenberg H, Jacob J, Crissman J, Al-Sarraf M. Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer. Am J Surg. 1982 Oct;144(4):445-448. Pubmedid: 6889819 .


• Kish J, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh J, Weaver A, Al-Sarraf M. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1982 Mar;66(3):471-474. Pubmedid: 7037180 .


• Crane L, Kish J, Ratanatharathorn V, Merline J, Raval M. Fatal syncytial virus pneumonia in a laminar airflow room. Jama. 1981 Jul;246(4):366-367. Pubmedid: 7241785 .












• Haas C, Fabian C, Stephens R, Kish J. Vindesine in head and neck cancer: a Southwest Oncology Group Phase II pilot study. Invest New Drugs. 1983 Win;1(4):339-340. Pubmedid: 6678881 .

Dr. Julie Kish is a senior member of the Genitourinary Oncology, Head & Neck, and Senior Adult Oncology Programs at Moffitt. She also is a professor at the University of South Florida (USF) College of Medicine.  Her research interests include clinical trials for head, neck and genitourinary cancers.

Dr. Kish received her bachelor’s, master’s degree and medical degree from Wayne State University in Detroit, Michigan.  She completed a residency in internal medicine and a fellowship in oncology at Wayne State University Affiliated Hospitals.

After completing her training, Dr. Kish was on the faculty at Wayne State School of Medicine and Case Western Reserve University in Cleveland, OH, as well as a physician with Henry Ford Health System in MI.  From 2000-2005, she was a member of the Moffitt team, serving as a principal investigator for both the Southwest Oncology Group (SWOG) and Eastern Cooperative Oncology Group (EOG) and a USF faculty member.

In 2006, Dr. Kish left Moffitt to join the San Antonio Cancer Institute in Texas, where she continued as a SWOG principal investigator, and served as a clinical professor at University of Texas Health Science Center.  She returned to Moffitt in 2008.

Dr. Kish is a member of the International Society of Geriatric Oncology and is listed in Best Doctors in America®.